Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Cash & Equivalents (2016 - 2025)

Tvardi Therapeutics' Cash & Equivalents history spans 13 years, with the latest figure at $20.7 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 34.42% to $20.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.7 million, a 34.42% decrease, with the full-year FY2025 number at $20.7 million, down 34.42% from a year prior.
  • Cash & Equivalents hit $20.7 million in Q4 2025 for Tvardi Therapeutics, down from $21.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TVRD hit a ceiling of $63.7 million in Q4 2022 and a floor of $13.5 million in Q4 2021.
  • Historically, Cash & Equivalents has averaged $36.9 million across 5 years, with a median of $35.6 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: tumbled 69.46% in 2021 and later skyrocketed 373.81% in 2022.
  • Tracing TVRD's Cash & Equivalents over 5 years: stood at $13.5 million in 2021, then skyrocketed by 373.81% to $63.7 million in 2022, then dropped by 18.77% to $51.8 million in 2023, then plummeted by 38.94% to $31.6 million in 2024, then tumbled by 34.42% to $20.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for TVRD at $20.7 million in Q4 2025, $21.4 million in Q3 2025, and $20.6 million in Q2 2025.